Loading news...
MannKind Corporation (NASDAQ: MNKD - Get Free Report) gapped up prior to trading on Wednesday after an insider bought additional shares in the company. The stock had previously closed at $2.61, but opened at $2.81. MannKind shares last traded at $2.7950, with a volume of 2,318,445 shares. Specifically, CEO Michael Castagna bought 100,000 shares of the
MannKind Corporation (MNKD) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Presentations highlight real‑world dosing and titration patterns in youth, and post‑prandial glucose management strategies using inhaled insulin in both adults and youth with T1D Data to be featured across oral and poster sessions at the Advanced Technologies & Treatments for Diabetes Conference (ATTD) PDUFA target action date for Afrezza in children and adolescents living with type 1 or type 2 diabetes set for May 29, 2026 DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced the settlement of the remaining $36.3 million aggregate principal amount of 2.50% convertible senior notes, all of which were tendered for conversion prior to the maturity date of March 1, 2026. The settlement was made on March 4, 2026, with $35.5 million in cash and 569,023 shares of MannKind common stock.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
MannKind Corporation (NASDAQ: MNKD - Get Free Report) traded down 6.6% during mid-day trading on Monday after Wall Street Zen downgraded the stock from a buy rating to a hold rating. The company traded as low as $3.03 and last traded at $3.0650. 1,435,401 shares changed hands during trading, a decline of 72% from the average
Investors weren't pleased with the biotech's bottom-line decline. It also missed the consensus analyst estimate for that metric.
MannKind Corporation (MNKD) Q4 2025 Earnings Call Transcript
While the top- and bottom-line numbers for MannKind (MNKD) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
MannKind (MNKD) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.03 per share a year ago.
Q4 2025 revenues of $112M, +46% vs. Q4 2024 Furoscix ® Q4 2025 net sales of $23M, +91% vs.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced Chief Executive Officer Michael Castagna, PharmD is scheduled to present and share business updates during the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, at 11:20 a.m. ET
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
MannKind Corporation is transitioning from a volatile biotech to a diversified, revenue-driven pharma, with FUROSCIX and Afrezza driving commercial momentum. MNKD's 2026 business outlook highlights expanding commercial assets, key regulatory milestones, and a strong pipeline, positioning 2026 as a potential breakout year. Afrezza's FDA label update removes adoption barriers, expanding its addressable market and supporting MNKD's long-term growth thesis.
/PRNewswire/ -- USA News Group News Commentary - Global capital is officially rotating into "Longevity Infrastructure" which is now valued at a massive $27
MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin
MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, and beaten-down REITs that offer solid income and turnaround potential. Part 5 of this series includes Hormel Foods, IonQ, Kodiak AI, Lara Exploration and MannKind.
MannKind (MNKD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
MannKind Corporation (NASDAQ: MNKD - Get Free Report) insider Stuart Tross sold 47,006 shares of the company's stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $6.33, for a total value of $297,547.98. Following the sale, the insider owned 985,007 shares of the company's stock, valued at $6,235,094.31.